Pridopidine for treating Huntington’s disease in adults

Pridopidine is in clinical development for the treatment of adult patients with Huntington’s disease (HD). HD is a hereditary neurodegenerative disorder (disease of the nervous system) caused by a genetic mutation in the Huntingtin gene (HTT) that leads to the progressive loss of nerve cells in the brain. This results in movement dysfunction, cognitive decline, and neuropsychiatric or behavioural symptoms. HD usually presents in mid-adulthood and progressively worsens over time. Currently, there is no cure for HD, and approved treatments only help to manage chorea symptoms (unpredictable muscle movements), with no benefits on other symptoms including function, cognition, behavioural and non-chorea motor symptoms.